147 related articles for article (PubMed ID: 30988027)
1. Siglec-9 Regulates an Effector Memory CD8
Haas Q; Boligan KF; Jandus C; Schneider C; Simillion C; Stanczak MA; Haubitz M; Seyed Jafari SM; Zippelius A; Baerlocher GM; Läubli H; Hunger RE; Romero P; Simon HU; von Gunten S
Cancer Immunol Res; 2019 May; 7(5):707-718. PubMed ID: 30988027
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
4. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
5. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
Egan H; Treacy O; Lynch K; Leonard NA; O'Malley G; Reidy E; O'Neill A; Corry SM; De Veirman K; Vanderkerken K; Egan LJ; Ritter T; Hogan AM; Redmond K; Peng L; Che J; Gatlin W; Jayaraman P; Sheehan M; Canney A; Hynes SO; Kerr EM; Dunne PD; O'Dwyer ME; Ryan AE
Cell Rep; 2023 May; 42(5):112475. PubMed ID: 37167967
[TBL] [Abstract][Full Text] [Related]
6. The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.
Stewart N; Daly J; Drummond-Guy O; Krishnamoorthy V; Stark JC; Riley NM; Williams KC; Bertozzi CR; Wisnovsky S
J Biol Chem; 2024 Feb; 300(2):105579. PubMed ID: 38141764
[TBL] [Abstract][Full Text] [Related]
7. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
Smith BAH; Deutzmann A; Correa KM; Delaveris CS; Dhanasekaran R; Dove CG; Sullivan DK; Wisnovsky S; Stark JC; Pluvinage JV; Swaminathan S; Riley NM; Rajan A; Majeti R; Felsher DW; Bertozzi CR
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215376120. PubMed ID: 36897988
[TBL] [Abstract][Full Text] [Related]
8. The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
Coccimiglio M; Chiodo F; van Kooyk Y
Br J Dermatol; 2024 Apr; 190(5):627-635. PubMed ID: 38197441
[TBL] [Abstract][Full Text] [Related]
9. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
10. Identification of therapeutic targets and prognostic biomarkers in the Siglec family of genes in tumor immune microenvironment of sarcoma.
Qi L; Jiang K; Zhao FF; Ren P; Wang L
Sci Rep; 2024 Jan; 14(1):577. PubMed ID: 38182638
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the Ability of Siglecs To Antagonize Fcγ Receptors.
McCord KA; Wang C; Anhalt M; Poon WW; Gavin AL; Wu P; Macauley MS
ACS Cent Sci; 2024 Feb; 10(2):315-330. PubMed ID: 38435516
[TBL] [Abstract][Full Text] [Related]
12. Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma.
Thiesler H; Gretenkort L; Hoffmeister L; Albers I; Ohlmeier L; Röckle I; Verhagen A; Banan R; Köpcke N; Krönke N; Feuerhake F; Behling F; Barrantes-Freer A; Mielke D; Rohde V; Hong B; Varki A; Schwabe K; Krauss JK; Stadelmann C; Hartmann C; Hildebrandt H
Clin Cancer Res; 2023 Jun; 29(12):2266-2279. PubMed ID: 37058255
[TBL] [Abstract][Full Text] [Related]
13. Activation of regulatory T cells triggers specific changes in glycosylation associated with Siglec-1-dependent inflammatory responses.
Wu G; Murugesan G; Nagala M; McCraw A; Haslam SM; Dell A; Crocker PR
Wellcome Open Res; 2021; 6():134. PubMed ID: 35224210
[No Abstract] [Full Text] [Related]
14. Immunosuppressive glycoproteins associate with breast tumor fibrosis and aggression.
Metcalf KJ; Hayward MK; Berens E; Ironside AJ; Stashko C; Hwang ES; Weaver VM
Matrix Biol Plus; 2022 Jun; 14():100105. PubMed ID: 35392183
[TBL] [Abstract][Full Text] [Related]
15. Optimized collaboration of the first and third signals endows robust activity to T cells within the immunocompetent tumor microenvironment.
Wei J; Lin X; Han W
Cell Mol Immunol; 2023 Nov; 20(11):1393-1394. PubMed ID: 37308558
[No Abstract] [Full Text] [Related]
16. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
17. Decreased erythrocyte binding of Siglec-9 increases neutrophil activation in sickle cell disease.
Kiser ZM; Lizcano A; Nguyen J; Becker GL; Belcher JD; Varki AP; Vercellotti GM
Blood Cells Mol Dis; 2020 Mar; 81():102399. PubMed ID: 31901888
[TBL] [Abstract][Full Text] [Related]
18. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.
Rodriguez E; Boelaars K; Brown K; Eveline Li RJ; Kruijssen L; Bruijns SCM; van Ee T; Schetters STT; Crommentuijn MHW; van der Horst JC; van Grieken NCT; van Vliet SJ; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
Nat Commun; 2021 Feb; 12(1):1270. PubMed ID: 33627655
[TBL] [Abstract][Full Text] [Related]
19. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
20. Functions and therapeutic targets of Siglec-mediated infections, inflammations and cancers.
Lin CH; Yeh YC; Yang KD
J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):5-24. PubMed ID: 31882261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
